Excalipoint Therapeutics and DP Technology have announced a strategic partnership to jointly develop a proprietary AI-powered TCE (Targeted Covalent Engagement) agentic platform. The collaboration aims to leverage artificial intelligence capabilities to advance the partners’ drug development efforts in the therapeutic space.
Search
